Management guidelines for preventing exposure to antineoplastics

Contents1.Introduction2.Methods2.1 Guideline project group2.2 Registration and methodology2.3 Guideline process2.3.1 Formulation of clinical questions2.3.2 Systematic literature review2.3.3 Consensus on recommendations3.Recommendations3.1 General principles3.2 Drug delivery,reception and storage3.3 Dispensing of antineoplastics3.4 Administration and carrying of antineoplastics3.5 Prevention measures for blood,excreta(urine and feces),and vomitus of patients3.6 Medical waste disposal4.Discussion5.Conclusions 1.Introduction The exposure of nurses,pharmacists,physicians,laboratory technicians,drug transportationstaff,,patients and caregivers in medical institutions to antineoplastics is a potential health hazard.Furthermore,these antineoplastics are potential contaminants if disposed inappropriately to the environment,thus making it an issue of immense concern in medical safety.A drug is declared hazardous if it shows one or more of the following six impacts on humans or animals:carcinogenicity,teratogenicity or other developmental toxicity,reproductive toxicity,organ toxicity at low doses,and genotoxicity.Hazardous drugs also include new drugs possessing structural and toxicity profiles similar to the existing hazardous drugs(1).

Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma

Retroperitoneal liposarcoma(RLPS)is the main subtype of retroperitoneal soft sarcoma(RSTS)and has a poor prognosis and few treatment options,except for surgery.The proteomic and metabolic profiles of RLPS have remained unclear.The aim of our study was to reveal the metabolic profile of RLPS.Here,we performed proteomic analysis(n=10),metabolomic analysis(n=51),and lipidomic analysis(n=50)of retroperitoneal dedifferentiated liposarcoma(RDDLPS)and retroperitoneal well-differentiated liposarcoma(RWDLPS)tissue and paired adjacent adipose tissue obtained during surgery.Data analysis mainly revealed that glycolysis,purine metabolism,pyrimidine metabolism and phospholipid formation were upregulated in both RDDLPS and RWDLPS tissue compared with the adjacent adipose tissue,whereas the tricarboxylic acid(TCA)cycle,lipid absorption and synthesis,fatty acid degradation and biosynthesis,as well as glycine,serine,and threonine metabolism were downregulated.Of particular importance,the glycolytic inhibitor 2-deoxy-D-glucose and pentose phosphate pathway(PPP)inhibitor RRX-001 significantly promoted the antitumor effects of the MDM2 inhibitor RG7112 and CDK4 inhibitor abemaciclib.Our study not only describes the metabolic profiles of RDDLPS and RWDLPS,but also offers potential therapeutic targets and strategies for RLPS.

Establishment of an orthotopic perirenal space xenograft mousemodel of retroperitoneal sarcoma

Dear Editor,Soft tissue sarcomas are a heterogeneous group of rare malignancies with mesenchymal origin that can arise at any anatomic site.They account for almost 1.5% of all malignancies in humans,with an increased incidence in young adults[1,2].The retroperitoneum is the primary site of 15%-20% of soft tissue sarcomas[3,4].